Intellia Therapeutics (NTLA) Accumulated Expenses (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Accumulated Expenses data on file, last reported at $9.3 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 77.15% year-over-year to $9.3 million in Q1 2026; TTM through Mar 2026 was $9.3 million, a 77.15% decrease from a year earlier, with the FY2025 full-year figure at $49.9 million, down 9.92% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $9.3 million, down from $49.9 million in the prior quarter.
• Over the last five years, Accumulated Expenses for NTLA reached as high as $67.0 million in Q4 2023 and fell as low as $9.3 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $31.5 million across 5 years, with a median of $21.8 million in 2022.
• Across the five-year window, Accumulated Expenses soared 301.99% in 2023 and slumped 77.15% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $21.8 million in 2022, then jumped by 207.73% to $67.0 million in 2023, then decreased by 17.4% to $55.4 million in 2024, then slipped by 9.92% to $49.9 million in 2025, then tumbled by 81.3% to $9.3 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $9.3 million in Q1 2026, $49.9 million in Q4 2025, and $16.8 million in Q3 2025.